Skip to main content
. 2015 Sep 4;10(9):e0137348. doi: 10.1371/journal.pone.0137348

Table 1. Clinical characteristics of patients with bronchiectasis.

Parameters CRS No CRS P value
No. of patients 47 101 -
Age (years) 43.6±14.8 45.0±13.4 0.58
Height (cm) 160.1±8.0 161.6±7.6 0.27
Weight (kg) 50.0 (11.5) 52.0 (10.8) 0.40
Females (No., %) 33 (70.2%) 59 (58.4%) 0.17
Body mass index (kg/m 2 ) 20.4±2.7 20.0 (4.3) 0.80
Body mass index <18.5 (No., %) 11 (23.4%) 33 (32.7%) 0.25
Age of bronchiectasis symptom onset (years) 30.3±16.1 30.7±17.1 0.91
Symptom onset for >10 years (No., %) 19 (40.4%) 40 (39.6%) 0.92
Duration of symptom onset (years) 13.3±9.7 14.3±14.2 0.65
24-hour sputum volume (ml) 20.0 (35.0) 20.0 (25.0) 0.44
Bronchiectasis Severity Index 6.4±3.4 5.0 (6.0) 0.19
Never-smokers (No., %) 39 (83.0%) 92 (91.1%) 0.15
Underlying causes
Post-infectious (No., %) 10 (21.3%) 30 (29.7%) 0.28
Other known causes (No., %) * 18 (38.3%) 22 (21.8%) 0.04
Idiopathic (No., %) 19 (40.4%) 49 (48.5%) 0.36

Numerical data were presented as mean ± standard deviation for normal distribution or otherwise median (interquartile range). Categorical data were expressed as number (percentage).

Data in bold indicated the comparisons with statistical significance.

* Of all bronchiectasis patients, other known causes consisted of immunodeficiency (n = 13, 8.8%), asthma (n = 8, 5.4%), gastroesophageal reflux (n = 6, 4.1%), aspergillosis (n = 2, 1.4%), rheumatoid arthritis (n = 2, 1.4%), Kartagener syndrome (n = 2, 1.4%), lung maldevelopment (n = 2, 1.4%), Young’s syndrome (n = 1, 0.7%), COPD (n = 1, 0.7%), lung sequestration (n = 1, 0.7%), yellow nail syndrome (n = 1, 0.7%) and diffuse panbronchiolitis (n = 1, 0.7%).

None of the patients had ever used inhaled antibiotics in this study.